Abstract
Iron deficiency is a frequent complication in chronically ill patients and in pregnant women. Iron status can now be characterised precisely and relatively easily by determining serum ferritin, transferritin saturation and if necessary hypochromic erythrocytes and the haemoglobin content of erythrocytes (CHr). Oral iron replacement is usually restricted by limited absorption and low tolerability. Intravenous iron therapy is possible in such cases and can be combined with rHuEPO (e.g. EPREX/ epoetin alfa) in severe cases. Iron saccharate (VENOFER) is commercially available in Switzerland and this permits high dose iron replacement without any danger of anaphylaxis or acute iron toxicity.
MeSH terms
-
Anemia, Iron-Deficiency / blood
-
Anemia, Iron-Deficiency / diagnosis
-
Anemia, Iron-Deficiency / drug therapy*
-
Anemia, Iron-Deficiency / epidemiology
-
Biomarkers / blood
-
Drug Therapy, Combination
-
Epoetin Alfa
-
Erythrocyte Count
-
Erythropoietin / therapeutic use*
-
Female
-
Ferric Compounds / therapeutic use*
-
Ferric Oxide, Saccharated
-
Ferritins / blood
-
Glucaric Acid
-
Hematinics / therapeutic use*
-
Hematocrit
-
Hemoglobins / metabolism
-
Humans
-
Injections, Intravenous
-
Pregnancy
-
Pregnancy Complications, Hematologic / drug therapy
-
Recombinant Proteins
-
Sucrose / therapeutic use*
-
Switzerland / epidemiology
-
Transferrin / metabolism
Substances
-
Biomarkers
-
Ferric Compounds
-
Hematinics
-
Hemoglobins
-
Recombinant Proteins
-
Transferrin
-
Erythropoietin
-
Sucrose
-
Epoetin Alfa
-
Ferritins
-
Ferric Oxide, Saccharated
-
Glucaric Acid